NCT04338555

Brief Summary

Patients undergoing elective orthopedics, urology, and general surgery will be included and randomly allocated to TEAS group or control group . After routine anesthesia induction and tracheal intubation, patients in TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points. For patients in the control group, the electrodes will be only attached to the corresponding sites, with no TEAS electrical stimulation given during the operation. The primary outcome is the incidence of POCD at Day 7 after surgery. The secondary outcomes include the incidence of POD during post-operative days 1-7, the incidence of POCD at Day 30 after surgery, and the serum levels of cytokines, including IL-1β、IL-6、TNF-α、MMP9 on Day 1 after surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 8, 2020

Completed
1.5 years until next milestone

Study Start

First participant enrolled

October 14, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 26, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 26, 2022

Completed
Last Updated

July 3, 2024

Status Verified

July 1, 2024

Enrollment Period

1 year

First QC Date

April 6, 2020

Last Update Submit

July 2, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • the incidence of POCD

    cognitive function of the patients will be analyzed with MMSE, Digital breadth, Number symbol, Visual regeneration, Color word conversion, Color Trail Marking Test (PartB) and CAM, and reflected by Z score with the following formula: Z=(Xafter-Xbefore)/SDbefore

    at Day 7 post-surgery

Secondary Outcomes (6)

  • the incidence of POCD

    at Day 30 post-surgery

  • the incidence of delirium

    from Day 1 to Day 7 post-surgery

  • serum IL-1β level

    at Day 1 post-surgery

  • serum IL-6 level

    at Day 1 post-surgery

  • serum TNF-α level

    at Day 1 post-surgery

  • +1 more secondary outcomes

Study Arms (2)

TEAS group

EXPERIMENTAL

Patients in the TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30min every hour. The stimulation will repeat until the end of surgery.

Procedure: Transcutaneous electrical acupoint stimulation

control group

NO INTERVENTION

In patients from the control group, the electrodes will only be attached to the corresponding sites, with no TEAS electrical stimulation given during the operation.

Interventions

TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30 min every hour during the surgery.

TEAS group

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≧ 60 years old;
  • communicate normally;
  • ASA Physical Status 1-2;
  • Patients will have elective orthopedics, urology or general surgeries under general anesthesia;
  • With an estimated surgery time of more than 2h;
  • Agree to participate the trial.

You may not qualify if:

  • Patients with brain diseases or history of brain diseases;
  • Preoperative diagnosis of cognitive impairment by subtle mental state (MMSE) less than 24 points;
  • Patients with history of neurological and psychological disorders including AD, stroke, and psychosis;
  • Severe hearing or visual impairment, illiteracy;
  • preoperative systolic blood pressure \>190mmHg, or diastolic blood pressure \>100mmHg;
  • Disagree to participate in this research;
  • Have used other medical electronic devices.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Renji Hospital

Shanghai, 200127, China

Location

Study Officials

  • Jie Tian

    RenJi Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

April 6, 2020

First Posted

April 8, 2020

Study Start

October 14, 2021

Primary Completion

October 26, 2022

Study Completion

October 26, 2022

Last Updated

July 3, 2024

Record last verified: 2024-07

Locations